Caenorhabditis elegans Galphaq regulates egg-laying behavior via a PLCbeta-independent and serotonin-dependent signaling pathway and likely functions both in the nervous system and in muscle.
egl-30 encodes the single C. elegans ortholog of vertebrate Galphaq family members. We analyzed the expression pattern of EGL-30 and found that it is broadly expressed, with highest expression in the nervous system and in pharyngeal muscle. We isolated dominant, gain-of-function alleles of egl-30 as intragenic revertants of an egl-30 reduction-of-function mutation. Using these gain-of-function mutants and existing reduction-of-function mutants, we examined the site and mode of action of EGL-30. On the basis of pharmacological analysis, it has been determined that egl-30 functions both in the nervous system and in the vulval muscles for egg-laying behavior. Genetic epistasis over mutations that eliminate detectable levels of serotonin reveals that egl-30 requires serotonin to regulate egg laying. Furthermore, pharmacological response assays strongly suggest that EGL-30 may directly couple to a serotonin receptor to mediate egg laying. We also examined genetic interactions with mutations in the gene that encodes the single C. elegans homolog of PLCbeta and mutations in genes that encode signaling molecules downstream of PLCbeta. We conclude that PLCbeta functions in parallel with egl-30 with respect to egg laying or is not the major effector of EGL-30. In contrast, PLCbeta-mediated signaling is likely downstream of EGL-30 with respect to pharyngeal-pumping behavior. Our data indicate that there are multiple signaling pathways downstream of EGL-30 and that different pathways could predominate with respect to the regulation of different behaviors.
Bastiani
Carol A
CA
Howard Hughes Medical Institute, California Institute of Technology, Pasadena, California 91125, USA.
Gharib
Shahla
S
Simon
Melvin I
MI
Sternberg
Paul W
PW
D000483:Alleles; D000818:Animals; D030801:Animals, Genetically Modified; D001522:Behavior, Animal; D017173:Caenorhabditis elegans / Q000187:drug effects / Q000502:physiology*; D029742:Caenorhabditis elegans Proteins / Q000378:metabolism*; D004843:Epistasis, Genetic; D005260:Female; D016166:Free Radical Scavengers / Q000494:pharmacology; D043802:GTP-Binding Protein alpha Subunits, Gq-G11 / Q000378:metabolism*; D005786:Gene Expression Regulation; D005799:Genes, Dominant; D007527:Isoenzymes / Q000378:metabolism; D008297:Male; D009132:Muscles / Q000502:physiology*; D009154:Mutation; D009420:Nervous System / Q000378:metabolism*; D010058:Oviposition / Q000187:drug effects / Q000502:physiology*; D054799:Phospholipase C beta; D011487:Protein Conformation; D011985:Receptors, Serotonin / Q000378:metabolism; D012701:Serotonin / Q000494:pharmacology; D015398:Signal Transduction; D010738:Type C Phospholipases / Q000378:metabolism; D014844:Vulva / Q000294:innervation / Q000502:physiology
D029742:Caenorhabditis elegans Proteins; C479565:Egl-30 protein, C elegans; D016166:Free Radical Scavengers; D007527:Isoenzymes; D011985:Receptors, Serotonin; D012701:Serotonin; D010738:Type C Phospholipases; D054799:Phospholipase C beta; D043802:GTP-Binding Protein alpha Subunits, Gq-G11